Paper Details

  1. Home
  2. Paper Details

Comparison of ceftibuten once daily and amoxicillin-clavulanate three times daily in the treatment of acute exacerbations of chronic bronchitis.

Author: GordonG R, McAdooM A, RiceK, SahnS A

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Ceftibuten once daily had a similar clinical success rate to amoxicillin-clavulanate three times daily in the treatment of patients with acute exacerbations of chronic bronchitis (AECB). Ceftibuten had a trend toward fewer gastrointestinal side effects.
Paper Details　
Original Abstract of the Article :
In medical practice, antibiotics are generally given empirically for the treatment of acute exacerbations of chronic bronchitis (AECB). To be effective, antibiotic therapy should be broad in spectrum, and it should also cover the common beta-lactamase-producing pathogens. In this multicenter, random...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0149-2918(98)80037-4

データ提供：米国国立医学図書館（NLM）

Ceftibuten vs Amoxicillin-Clavulanate for Chronic Bronchitis

The world of respiratory infections is a vast desert, filled with challenges and complexities. This study tackles a common challenge, acute exacerbations of chronic bronchitis, by comparing the effectiveness of two antibiotic treatments: ceftibuten and amoxicillin-clavulanate. The researchers, like explorers navigating a treacherous landscape, conducted a randomized, controlled trial to assess the efficacy and safety of these treatments. They found that ceftibuten, taken once daily, was equally effective as amoxicillin-clavulanate, taken three times daily, in treating these exacerbations, while potentially offering a more convenient and comfortable journey through the desert of illness.

Ceftibuten: A Potential Oasis for Chronic Bronchitis

The study found that ceftibuten, like a refreshing oasis in the desert, provided similar clinical success as amoxicillin-clavulanate but with a trend toward fewer gastrointestinal side effects. This is significant, as a more tolerable treatment can make the journey through illness more comfortable. It's important to note that both treatments were effective, but ceftibuten's convenience and potentially improved tolerability make it a valuable option for patients.

Navigating the Desert of Chronic Bronchitis

The research on ceftibuten for acute exacerbations of chronic bronchitis is like finding a new path through a familiar desert. It offers a potentially more convenient and comfortable option for patients, while still providing effective treatment. It's important to remember that a doctor's guidance is essential in choosing the best treatment based on individual needs and the specific characteristics of the desert of chronic bronchitis.

Dr. Camel's Conclusion

This research on ceftibuten for chronic bronchitis is like a camel discovering a new spring in the desert. It offers a potentially more convenient and tolerable treatment option while maintaining effectiveness. It's a reminder that even in the vast and challenging desert of respiratory illness, there are often new paths to explore, leading to better treatment and a more comfortable journey.

Date :
  1. Date Completed 1998-04-30
  2. Date Revised 2019-09-21
Further Info :

Pubmed ID

9522107

DOI: Digital Object Identifier

10.1016/s0149-2918(98)80037-4

Related Literature

Article Analysis
・Side Effects of ceftibuten
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.